New York, NY (PRWEB) May 04, 2013
The IUD safety advocates at DrugRisks.com are announcing new updates to the site for women who have used the vaginal ring contraceptive NuvaRing. This week, device maker Merck released records indicating use of the device have slowed since the end of last year*.
DrugRisks was designed to give patients using popular prescription drugs and devices the latest drug news, warnings, research and legal news. Visitors can find out if others are experiencing similar side effects and decide if they need legal advice.
Health experts have linked contraceptives like NuvaRing to higher risks of blood clots than traditional birth control pills. Last year, the New England Journal of Medicine published a study finding vaginal ring contraceptives could relate to a 2.5 to 3-fold increased risk of blood clots**.
Almost 1,100 patients have already filed a NuvaRing lawsuit alleging blood clots in a special federal court in Missouri. The formal case is known as In re: NuvaRing Products Liability Litigation, No. 08-md-1964, JPML, Eastern District Missouri.
Now, DrugRisks has learned that the latest financial records from NuvaRing maker Merck show sales of the device dropped from $164 million at the end of 2012 to $151 million in the first quarter of 2013, a decline of 8%*.
Anyone who suffered a blood clot, stroke, DVT or pulmonary embolism after using NuvaRing is urged to contact DrugRisks.com or speak with a lawyer about their legal rights as soon as possible.
Due to the specialized nature of federal MDL drug injury cases, DrugRisks only recommends lawyers and law firms who have already handled NuvaRing lawsuits.
Copyright©2012 Vocus, Inc.
All rights reserved